Adjuvants for enhancing the immunogenicity of whole tumor cell vaccines

International Reviews of Immunology

Volumn 30, Issue 2-3, 2011, Pages 150-182

  Chiang, Cheryl Lai Lai ^a   Kandalaft, Lana E ^a   Coukos, George ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

adjuvants; cytokines; immunogenicity; ovarian carcinoma; Toll like receptor agonists; Whole tumor cell vaccine

Indexed keywords

ALUMINUM POTASSIUM SULFATE; BCG VACCINE; BEVACIZUMAB; CISPLATIN; CPG OLIGODEOXYNUCLEOTIDE; CYCLOPHOSPHAMIDE; DENDRITIC CELL VACCINE; DOCETAXEL; DOXORUBICIN; GAMMA INTERFERON; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; HYPOCHLOROUS ACID; IMMUNOLOGICAL ADJUVANT; KEYHOLE LIMPET HEMOCYANIN; LIPOSOME; MACROPHAGE ACTIVATING LIPOPEPTIDE 2; MELACINE; MONTANIDE ISA 51; PHOSPHORYL LIPID A; PLACEBO; POLYINOSINIC POLYCYTIDYLIC ACID; PREDNISONE; RINTATOLIMOD; TOLL LIKE RECEPTOR AGONIST; TUMOR CELL VACCINE; UNINDEXED DRUG; VIRUS ONCOLYSATE; WART VIRUS VACCINE;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL LYSATE; CELLULAR IMMUNITY; CHRONIC FATIGUE SYNDROME; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; DELAYED HYPERSENSITIVITY; DISEASE FREE SURVIVAL; DNA MODIFICATION; DRUG HYPERSENSITIVITY; EMULSION; FREEZE THAWING; GYNECOLOGIC CANCER; HERPES SIMPLEX VIRUS; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOMODULATION; INFLUENZA VIRUS A; KIDNEY CANCER; KIDNEY FAILURE; LIVER TOXICITY; LOW DRUG DOSE; LUNG CANCER; MELANOMA; METASTASIS; NEPHROTOXICITY; NEWCASTLE DISEASE PARAMYXOVIRUS; NONHUMAN; OVARY CANCER; OVARY CARCINOMA; OXIDATION; PANCREAS CARCINOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); SHOCK; TREATMENT RESPONSE; ULTRAVIOLET B RADIATION; UTERUS CANCER; UTERUS SARCOMA; VIRUS INACTIVATION; VIRUS INFECTION;

ADJUVANTS, IMMUNOLOGIC; ANTIBODY FORMATION; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEMOCYANIN; HUMANS; IMMUNOTHERAPY; MANNITOL; OLEIC ACIDS; OVARIAN NEOPLASMS; T-LYMPHOCYTES; TOLL-LIKE RECEPTORS; TREATMENT OUTCOME;

EID: 79955859969     PISSN: 08830185     EISSN: 15635244     Source Type: Journal    
DOI: 10.3109/08830185.2011.572210     Document Type: Article

References (223)

1. Zajac AJ, Blattman JN, Murali-Krishna K, et al. Viral immune evasion due to persistence of activated T cells without efector function. J Exp Med 1998;188:2205-2213. (Pubitemid 29028493)
2. Neller MA, López JA, Schmidt CW. Antigens for cancer immunotherapy. Semin Immunol 2008;20:286-295.
3. Sauter B, Albert ML, Francisco L, et al. Consequences of cell death: Exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J Exp Med 2000;191:423-434.
4. Somersan S, Larsson M, Fonteneau JF, et al. Primary tumor tissue lysates are enriched in heat shock proteins and induce the maturation of human dendritic cells. J Immunol 2001;167:4844-4852. (Pubitemid 33009712)
5. Asea A, Kraeft S-K, Kurt-Jones EA, et al. HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role as a chaperone and cytokine. Nat Med 2000;6:435-442. (Pubitemid 30208161)
6. Wang X-Y, Arnouk H, Chen X, et al. Extracellular targeting of endoplasmic reticulum chaperone glucose-regulated protein 170 enhances tumor immunity to a poorly immunogenic melanoma. J Immunol 2006;177:1543-1551. (Pubitemid 44092488)
7. Scafdi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers infammation. Nature 2002;418:191-195. (Pubitemid 34773774)
8. Wang H, Bloom O, Zhang M, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999;285:248-251. (Pubitemid 29329996)
9. Apetoh L, Ghiringhelli F, Tesniere A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007;13:1050-1059. (Pubitemid 47517504)
10. Hu D-E, Moore AM, Tomsen LL, Brindle KM. Uric acid promotes tumor immune rejection. Cancer Res 2004;64:5059-5062. (Pubitemid 39006518)
11. Shi Y, Evans JE, Rock KL. Molecular identifcation of a danger signal that alerts the immune system to dying cells. Nature 2003;425:516-521. (Pubitemid 37237047)
12. Watts C. Capture and processing of exogenous antigens for presentation on MHC molecules. Annu Rev Immunol 1997;15:821-850. (Pubitemid 27169300)
13. Li M, Davey GM, Sutherland RM, et al. Cell-associated ovalbumin is cross-presented much more efciently than soluble ovalbumin in vivo. J Immunol 2001;166:6099-6103. (Pubitemid 32440737)
14. Lopez MN, Pereda C, Segal G, et al. Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-Specific delayed Type IV hypersensitivity response and reduction of tumor growth factor (beta)-expressing T cells. J Clin Oncol 2009;27:945-952.
15. Hernando J, Park T, Kübler K, et al. Vaccination with autologous tumour antigen-pulsed dendritic cells in advanced gynaecological malignancies: Clinical and immunological evaluation of a phase I trial. Cancer Immunol Immunother 2002;51:45-52. (Pubitemid 34158522)
16. GhiringhelliF, Menard C, Puig P, etal.Metronomic cyclophosphamideregimen selectively depletes CD4 & CD25 regulatory T cells and restores T and NK efector functions in end stage cancer patients. Cancer Immunol Immunother 2007;56:641-648. (Pubitemid 46348738)
17. Kandalaft LE, Facciabene A, Buckanovich RJ, Coukos G. Endothelin B receptor, a new target in cancer immune therapy. Clin Cancer Res 2009;15:4521-4528.
18. Fadok VA, Bratton DL, Rose DM, et al. A receptor for phosphatidylserine- Specific clearance of apop-totic cells. Nature 2000;405:85-90. (Pubitemid 30321820)
19. Larsson M, Fonteneau JF, Bhardwaj N. Dendritic cells resurrect antigens from dead cells. Trends Immunol 2001;22:141-148. (Pubitemid 32675261)
20. Jenne L, Arrighi J-F, Jonuleit H, et al. Dendritic cells containing apoptotic melanoma cells prime human CD8+ T cells for efcient tumor cell lysis. Cancer Res 2000;60:4446-4452. (Pubitemid 32103624)
21. Obeid M, Tesniere A, Ghiringhelli F, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007;13:54-61. (Pubitemid 46067386)
22. Obeid M, Panaretakis T, Joza N, et al. Calreticulin exposure is required for the immunogenicity of -irradiation and UVC light-induced apoptosis. Cell Death Difer 2007;14:1848-1850. (Pubitemid 47423653)
23. Tian J, Avalos AM, Mao S-Y, et al. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol 2007;8:487-496. (Pubitemid 46605917)
24. Bell CW, Jiang W, Reich CF, III, Pisetsky DS. The extracellular release of HMGB1 during apoptotic cell death. Am J Physiol Cell Physiol 2006;291:C1318-C1325. (Pubitemid 44878603)
25. Rovere P, Peri G, Fazzini F, et al. The long pentraxin PTX3 binds to apoptotic cells and regulates their clearance by antigen-presenting dendritic cells. Blood 2000;96:4300-4306.
26. Baruah P, Propato A, Dumitriu IE, et al. The pattern recognition receptor PTX3 is recruited at the synapse between dying and dendritic cells, and edits the cross-presentation of self, viral, and tumor antigens. Blood 2006;107:151-158. (Pubitemid 43053537)
27. Benencia F, Courreges M, Coukos G. Whole tumor antigen vaccination using dendritic cells: Comparison of RNA electroporation and pulsing with UV-irradiated tumor cells. J Transl Med 2008;6:21-34.
28. Courreges MC, Benencia F, Conejo-Garcia JR, et al. Preparation of apoptotic tumor cells with replication-incompetent HSV augments the efcacy of dendritic cell vaccines. Cancer Gene Ter 2005;13:182-193.
29. Schlienger K, Chu CS, Woo EY, et al. TRANCE-and CD40 Ligand-matured dendritic cells reveal MHC Class I-restricted T cells Specific for autologous tumor in late-stage ovarian cancer patients. Clin Cancer Res 2003;9:1517-1527. (Pubitemid 36418410)
30. Baars A, Claessen AME, Van Den Eertwegh AJM, et al. Skin tests predict survival after autol-ogous tumor cell vaccination in metastatic melanoma: Experience in 81 patients. Ann Oncol 2000;11:965-970.
31. Hodi FS, Butler M, Oble DA, et al. Immunologic and clinical efects of antibody blockade ofcytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci USA 2008;105:3005-3010. (Pubitemid 351723658)
32. Hodi FS, Mihm MC, Soifer RJ, et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA 2003;100:4712-4717. (Pubitemid 36457795)
33. Dillman RO, DePriest C, DeLeon C, et al. Patient-Specific vaccines derived from autologous tumor cell lines as active Specific immunotherapy: Results of exploratory phase I/II trials in patients with metastatic melanoma. Cancer Biother Radiopharm 2007;22:309-321. (Pubitemid 47067889)
34. Dillman RO, Nanci AA, Williams ST, et al. Durable complete response of refractory, progressing metastatic melanoma after treatment with a patient-Specific vaccine. Cancer Biother Radiopharm 2010;25:553-557.
35. Allison MED, Fearon DT. Enhanced immunogenicity of aldehyde-bearing antigens: A possible link between innate and adaptive immunity. Eur J Immunol 2000;30:2881-2887.
36. Marcinkiewicz J, Chain BM, Olszowska E, et al. Enhancement of immunogenic properties of oval-bumin as a result of its chlorination. Intl J Biochem 1991;23:1393-1395.
37. Marcinkiewicz J, Olszowska E, Olszowski S, Zgliczynski J. Enhancement of trinitrophenyl-Specific humoral response to TNP proteins as the result of carrier chlorination. Immunology 1992;76:385-388.
38. StarkJM. Immunologicaladjuvance of metabolic origin:Oxidative stress, postulatedimpaired function of thiol proteases and immunogenicity. Scand J Immunol 1998;48:475-479. (Pubitemid 28505670)
39. Callahan MK, Chaillot D, Jacquin C, et al. Diferential acquisition of antigenic peptides by Hsp70 and Hsc70 under oxidative conditions. J Biol Chem 2002;277:33604-33609.
40. Reth M. Hydrogen peroxide as second messenger in lymphocyte activation. Nat Immunol 2002;3:1129-1134. (Pubitemid 35469696)
41. Tatla S, Woodhead V, Foreman JC, Chain BM. The role of reactive oxygen species in triggering proliferation and IL-2 secretion in T cells. Free Rad Biol Med 1999;26:14-24.
42. Chiang CL, Ledermann JA, Egla A, et al. Oxidation of ovarian epithelial cancer cells by hypochlorous acid enhances immunogenicity and stimulates T cells that recognize autologous primary tumor. Clin Cancer Res 2008;14:4898-4907.
43. Chiang C, Ledermann J, Rad AN, Katz D, Chain B. Hypochlorous acid enhances immunogenicity and uptake of allogeneic ovarian tumor cells by dendritic cells to cross-prime tumor-Specific T cells. Cancer Immunol Immunother 2006;55:1384-1395. (Pubitemid 44187670)
44. Anderson MM, Hazen SL, Hsu FF, Heinecke JW. Human neutrophils employ the myeloperoxidase-hydrogen peroxide-chloride system to convert hydroxy-amino acids into glycolaldehyde, 2-hydroxypropanal, and acrolein. A mechanism for the generation of highly reactive alpha-hydroxy and alpha,beta-unsaturated aldehydes by phagocytes at sites of infammation. J Clin Invest 1997;99:424-432. (Pubitemid 27414799)
45. Anderson MM, Requena JR, Crowley JR, et al. The myeloperoxidase system of human phagocytes generates Nε-(carboxymethyl)lysine on proteins: A mechanism for producing advanced glycation end products at sites of infammation. J Clin Invest 1999;104:103-113. (Pubitemid 29534350)
46. Hazen SL, Hsu FF, Mueller DM, et al. Human neutrophils employ chlorine gas as an oxidant during phagocytosis. J Clin Invest 1996;98:1283-1289. (Pubitemid 26322052)
47. Carrasco-Maŕn SE, Paz-Miguel J, López-Mato P, et al. Oxidation of defned antigens allows protein unfolding and increases both proteolytic processing and exposes peptide epitopes which are recognized by Specific T cells. Immunology 1998;95:314-321. (Pubitemid 28505685)
48. Feder ME, Hofmann GE. Heat-shock proteins, molecular chaperones, and the stress response: Evolutionary and ecological physiology. Annu Rev Physiol 1999;61:243-282. (Pubitemid 29143171)
49. Kakutani M, Masaki T, Sawamura T. A platelet-endothelium interaction mediated by lectin-like oxidized low-density lipoprotein receptor-1. Proc Natl Acad Sci USA 2000;97:360-364. (Pubitemid 30055836)
50. Oka K, Sawamura T, Kikuta K-I, et al. Lectin-like oxidized low-density lipoprotein receptor 1 mediates phagocytosis of aged/apoptotic cells in endothelial cells. Proc Natl Acad Sci USA 1998;95:9535-9540. (Pubitemid 28506266)
51. Moriwaki H, Kume N, Sawamura T, et al. Ligand specifcity of LOX-1, a novel endothelial receptor for oxidized low density lipoprotein. Arterioscler Tromb Vasc Biol 1998;18:1541-1547. (Pubitemid 28465404)
52. Jono T, Miyazaki A, Nagai R, et al. Lectin-like oxidized low density lipoprotein receptor-1 (LOX-1) serves as an endothelial receptor for advanced glycation end products (AGE). FEBS Lett 2002;511:170-174. (Pubitemid 34127844)
53. Shimaoka T, Kume N, Minami M, et al. LOX-1 Supports adhesion of Gram-positive and Gram-negative bacteria. J Immunol 2001;166:5108-5114. (Pubitemid 32280724)
54. Marsche G, Levak-Frank S, Quehenberger O, et al. Identifcation of the human analog of SR-BI and LOX-1 as receptors for hypochlorite-modifed high-density lipoprotein on human umbilical venous endothelial cells. FASEB J 2001;15:1095-1097.
55. Delneste Y, Magistrelli G, Gauchat J-F, et al. Involvement of LOX-1 in dendritic cell-mediated antigen cross-presentation. Immunity 2002;17:353-362. (Pubitemid 35279555)
56. Prokopowicz ZM, Arce F, Biedron R, et al. Hypochlorous acid: A natural adjuvant that facilitates antigen processing, cross-priming, and the induction of adaptive immunity. J Immunol 2010;184:824-835.
57. Marsche G, Zimmermann R, Horiuchi S, et al. Class B scavenger receptors CD36 and SR-BI are receptors for hypochlorite-modifed low density lipoprotein. J Biol Chem 2003;278:47562-47570. (Pubitemid 37523199)
58. Ohgami N, Nagai R, Miyazaki A, et al. scavenger receptor Class B Type I-mediated reverse cholesterol transport is inhibited by Advanced End products. J Biol Chem 2001;276:13348-13355.
59. Eager R, John N. GM-CSF gene-transduced tumor vaccines. Mol Ter 2005;12:18-27. (Pubitemid 40862352)
60. Simons J, Carducci M, Mikhak B, et al. Phase I/II trial of an allogeneic cellular immunotherapy in hormone-nä?ve prostate cancer. Clin Cancer Res 2006;12:3394-3401.
61. Small E, Sacks N, Nemunaitis J, et al. Granulocyte macrophage colony-stimulating factor-secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin Cancer Res 2007;13:3883-3891. (Pubitemid 47037595)
62. Petrylak DP, Macarthur RB, O'Connor J, et al. Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J Clin Oncol 1999;17:958-967. (Pubitemid 29109329)
63. Savarese DM, Halabi S, Hars V, et al. Phase II Study of docetaxel, estramustine, and low-dose hy-drocortisone in men with hormone-refractory prostate cancer: A fnal report of CALGB 9780. J Clin Oncol 2001;19:2509-2516. (Pubitemid 32391222)
64. Small E, Tchekmedyian N, Rini B, et al. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res 2007;13:1810-1815. (Pubitemid 46952950)
65. Antonarakis ES,DrakeCG. Current status of immunological therapies for prostate cancer. Curr Opin Urol 2010;20:241-246.
66. Melcher A, Todryk S, Hardwick N, et al. Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression. Nat Med 1998;4:581-587. (Pubitemid 28237357)
67. Arroyo PJ, Bash JA, Wallack MK. Active Specific immunotherapy with vaccinia colon oncolysate enhances the immunomodulatory and antitumor efects of interleukin-2 and interferon α in a murine hepatic metastasis model. Cancer Immunol Immunother 1990;31:305-311. (Pubitemid 20230294)
68. Sinkovics JG. Viral oncolysates as human tumor vaccines. Int Rev Immunol 1991;7259-7287.
69. Berthier-Vergnes O, Portoukalian J, Lefthériotis E, Doré J-F. Induction of IgG antibodies directed to a Mr 31,000 melanoma antigen in patients immunized with Vaccinia Virus melanoma oncolysates. Cancer Res 1994;54:2433-2439.
70. Marc KW, Muthukumaran S, Charles MB, et al. Surgical adjuvant active Specific immunotherapy for patients with stage III melanoma: The fnal analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial. J Am Coll Surg 1998;187:69-79.
71. Freedman R, Edwards C, Bowen J, et al. Viral oncolysates in patients with advanced ovarian cancer. Gynecol Oncol 1988;29:337-347. (Pubitemid 18079530)
72. Ioannides C, Platsoucas C, Freedman R. Immunological efects of tumor vaccines: II. T cell responses directed against cellular antigens in the viral oncolysates. In Vivo 1990;4:17-24. (Pubitemid 20180056)
73. Ioannides C, Platsoucas C, Patenia R, et al. T-cell functions in ovarian cancer patients treated with viral oncolysates: I. Increased helper activity to immunoglobulins production. Anticancer Res 1990;10:645-653. (Pubitemid 20237811)
74. Schirrmacher V. Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modifedbyvirus infection: Improvementof patient survival based on improved antitumor immune memory. Cancer Immunol Immunother 2005;54:587-598. (Pubitemid 40613037)
75. Ahlert T, Sauerbrei W, Bastert G, et al. Tumor-cell number and viability as quality and efcacy parameters of autologous virus-modifed cancer vaccines in patients with breast or ovarian cancer. J Clin Oncol 1997;15:1354-1366. (Pubitemid 27167367)
76. Coukos G, Makrigiannakis A, Kang EH, et al. Molnar-Kimber oncolytic Herpes Simplex Virus-1 lacking ICP34.5 induces p53-independent death and is efcacious against chemotherapy-resistant ovarian cancer. Clin Cancer Res 2000;6:3342-3353. (Pubitemid 30637766)
77. Aubert M, O'Toole J, Blaho JA. Induction and prevention of apoptosis in human HEp-2 cells by Herpes Simplex Virus Type 1. J Virol 1999;73:10359-10370.
78. Galvan V, Roizman B. Herpes simplex virus 1 induces and blocks apoptosis at multiple steps during infection and protects cells from exogenous inducers in a cell-type-dependent manner. Proc Natl Acad Sci USA 1998;95:3931-3936.
79. Miklos Z, Danis VA, Adams S, et al. In vivo production of cytokines and β (C-C) chemokines in human recurrent Herpes Simplex lesions-do Herpes Simplex Virus-infected keratinocytes contribute to their production? J Infect Dis 1998;177:827-838. (Pubitemid 28155133)
80. Benencia F, Coukos G. Biological therapy with oncolytic Herpesvirus. In: Coukos G, Berchuck A, Ozols R, eds. Ovarian Cancer. Vol. 622: New York: Springer; 2008. 221-233 pp.
81. Benencia F, Courrèges M, Fraser N, Coukos G. Herpes virus oncolytic therapy reverses tumor immune dysfunction and facilitates tumor antigen presentation. Cancer Biol Ter 2008;7:1194-1205.
82. Jugovic P, Hill AM, Tomazin R, et al. Inhibition of major histocompatibility complex Class I antigen presentation in pig and primate cells by Herpes Simplex Virus Type 1 and 2 ICP47. J Virol 1998;72:5076-5084. (Pubitemid 28215688)
83. Samaniego L, Wu N, DeLuca N. The herpes simplex virus immediate-early protein ICP0 afects transcription from the viral genome and infected-cell survival in the absence of ICP4 and ICP27. J Virol 1997;71:4614-4625. (Pubitemid 27204154)
84. Chiang CL-L, Benencia F, Coukos G. Whole tumor antigen vaccines. Semin Immunol 2010;22:132-143.
85. Berd D, Sato T, Maguire HC, et al. Immunopharmacologic analysis of an autologous, hapten-modifed human melanoma vaccine. J Clin Oncol 2004;22:403-415. (Pubitemid 41079768)
86. Berd D, Sato T, Cohn H, et al. Treatment of metastatic melanomawith autologous, hapten-modifed melanoma vaccine: Regression of pulmonary metastases. Int J Cancer 2001;94:531-539.
87. Miyake K. Innate immune sensing of pathogens and danger signals by cell surface Toll-like receptors. Semin Immunol 2007;19:3-10. (Pubitemid 46498750)
88. Hoebe K, Janssen E, Beutler B. The interface between innate and adaptive immunity. Nat Immunol 2004;5:971-974. (Pubitemid 41057712)
89. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004;4:499-511. (Pubitemid 38931765)
90. Malyala P, Chesko J, Ugozzoli M, et al. The potency of the adjuvant, CpG oligos, is enhanced by encapsulation in PLG microparticles. J Pharm Sci 2008;97:1155-1164.
91. Vajdy M, Selby M, Medina-Selby A, et al. Hepatitis C virus polyprotein vaccine formulations capable of inducing broad antibody and cellular immune responses. J Gen Virol 2006;87:2253-2262. (Pubitemid 44178102)
92. O'Hagan DT, Singh M, Kazzaz J, et al. Synergistic adjuvant activity of immunostimulatory DNA and oil/water emulsions for immunization with HIV p55 gag antigen. Vaccine 2002;20:3389-3398. (Pubitemid 35245822)
93. Wack A, Baudner BC, Hilbert AK, et al. Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to infuenza vaccine in mice. Vaccine 2008;26:552-561.
94. Garçon N, Chomez P, Van Mechelen M. GlaxoSmithKline adjuvant systems in vaccines: Concepts, achievements and perspectives. Expert Rev Vaccines 2007;6:723-739. (Pubitemid 47607848)
95. Brandau S, Suttmann H. Tirty years of BCG immunotherapy for non-muscle invasive bladder cancer: A success story with room for improvement. Biomed Pharmacother 2007;61:299-305. (Pubitemid 47189735)
96. Uehori J, Matsumoto M, Tsuji S, et al. Simultaneous blocking of human toll-like receptors 2 and 4 suppresses myeloid dendritic cell activation induced by Mycobacterium bovis Bacillus Calmette-Guerin Peptidoglycan. Infect Immun 2003;71:4238-4249. (Pubitemid 36919886)
97. Sondak VK, Sosman JA. Results of clinical trials with an allogeneic melanoma tumor cell lysate vaccine: Melacine®. Semin Cancer Biol 2003;13:409-415. (Pubitemid 38156132)
98. Alberts DS, Mason-Liddil N, O'Toole RV, et al. Randomized phase III trial of chemoimmunother-apy in patients with previously untreated stage III, optimal disease ovarian cancer: A Southwest Oncology Group study. Gynecol Oncol 1989;32:16-21. (Pubitemid 19029860)
99. Alberts DS, Moon TE, Stephens RA. Randomized study of chemoimmunotherapy for advanced ovarian carcinoma: A preliminary report of a Southwest Oncology Group study. Cancer Treat Rep 1979;63:325-331. (Pubitemid 9151522)
100. Creasman WT, Gall S, Bundy BN, et al. Second-look laparotomy in the patient with minimal residual stage III ovarian cancer (a Gynecologic Oncology Group study). Gynecol Oncol 1989;35:378-382. (Pubitemid 20025906)
101. Deiters U, Muhlradt PF. Mycoplasmal lipopeptide MALP-2 induces the chemoattractant proteins macrophage infammatory protein 1 alpha (MIP-1alpha), monocyte chemoattractant protein 1, and MIP-2 and promotes leukocyte infltration in mice. Infect Immun 1999;67:3390-3398. (Pubitemid 29291507)
102. Kaufmann A, Muhlradt PF, Gemsa D, Sprenger H. Induction of cytokines and chemokines in human monocytes by mycoplasma fermentans-derived lipoprotein MALP-2. Infect Immun 1999;67:6303-6308.
103. Schneider C, Schmidt T, Ziske C, et al. Tumour suppression induced by the macrophage activating lipopeptide MALP-2 in an ultrasound guided pancreatic carcinoma mouse model. Gut 2004;53:355-361. (Pubitemid 38241329)
104. ShinguK, Kruschinski C, LuhrmannA, etal. Intratracheal macrophage-activatinglipopeptide-2 reduces metastasis in the rat lung. Am J Respir Cell Mol Biol 2003;28:316-321. (Pubitemid 36238008)
105. Schmidt J, Welsch T, Jager D, et al. Intratumoural injection of the toll-like receptor-2/6 agonist 'macrophage-activating lipopeptide-2' in patients with pancreatic carcinoma: A phase I/II trial. Br J Cancer 2007;97:598-604. (Pubitemid 47339882)
106. Verdijk RM, Mutis T, Esendam B, et al. Polyriboinosinic Polyribocytidylic Acid (Poly(I:C)) induces stable maturation of functionally active human dendritic cells. J Immunol 1999;163:57-61. (Pubitemid 29295824)
107. Jongbloed SL, Kassianos AJ, McDonald KJ, et al. Human CD141+ (BDCA-3) +dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. J Exp Med 2010;207:1247-1260.
108. Robinson R, DeVita V, Levy H, et al. A phase I-II trial of multiple-dose polyriboinosic-polyribocytidylic acid in patieonts with leukemia or solid tumors. J Natl Cancer Inst 1976;57:599-603.
109. Tompson KA, Strayer DR, Salvato PD, et al. Results of a double-blind placebo-controlled study of the double-stranded RNA drug polyI:polyC12U in the treatment of HIV infection. Eur J Clin Microbiol Infect Dis 1996;15:580-587.
110. Strayer DR, Carter WA, BrodskyI, et al. A controlled clinical trial with a specifcally confgured RNA drug, Poly(I). Poly(C12U), in chronic fatigue syndrome. Clin Infect Dis 1994;18:S88-S95.
111. Navabi H, Jasani B, Reece A, et al. A clinical grade poly I:C-analogue (Ampligen®) promotes optimal DC maturation and T1-type T cell responses of healthy donors and cancer patients in vitro. Vaccine 2009;27:107-115.
112. Trumpfheller C, Caskey M, Nchinda G, et al. The microbial mimic poly IC induces durable and protective CD4+ T cell immunity together with a dendritic cell targeted vaccine. Proc Natl Acad Sci USA 2008;105:2574-2579. (Pubitemid 351520555)
113. Cornell CJ, Smith K, Cornwell Gr, et al. Systemic effects of intravenous polyriboinosinic-polyribocytidylic acid in man. J Natl Cancer Inst 1976;57:1211-1216. (Pubitemid 8009077)
114. Freeman A, Al-Bussam N, O'Malley J, et al. Pharmacologic effects of polyinosinic-polycytidylic acid in man. J Med Virol 1977;1:79-93.
115. Sloat B, Cui Z. Nasal Immunization with anthrax protective antigen protein adjuvanted with polyriboinosinic-polyribocytidylic acid induced strong mucosal and systemic immunities. Pharma Res 2006;23:1217-1226. (Pubitemid 43946144)
116. Ichinohe T, Kawaguchi A, Tamura S-I, et al. Intranasal immunization with H5N1 vaccine plus Poly I:Poly C12U, a Toll-like receptor agonist, protects mice against homologous and heterologous virus challenge. Microbes Infect 2007;9:1333-1340. (Pubitemid 47539208)
117. Kagan JC, Su T, Horng T, et al. TRAM couples endocytosis of Toll-like receptor 4 to the induction of interferon-. Nat Immunol 2008;9:361-368. (Pubitemid 351405105)
118. Kanzler H, Barrat FJ, Hessel EM, Cofman RL. Terapeutic targeting of innate immunity with Tolllike receptor agonists and antagonists. Nat Med 2007;13:552-559. (Pubitemid 46830615)
119. Mata-Haro V, Cekic C, Martin M, et al. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science 2007;316:1628-1632. (Pubitemid 46982038)
120. Baldridge JR, Crane RT. Monophosphoryl lipid A (MPL) formulations for the next generation of vaccines. Methods 1999;19:103-107. (Pubitemid 29497759)
121. Martin M, Michalek SM, Katz J. Role of innate immune factors in the adjuvant activity of monophosphoryl lipid A. Infect Immun 2003;71:2498-2507. (Pubitemid 36519862)
122. Ten Brinke A, Van Schijndel G, Visser R, et al. Monophosphoryl lipid A plus IFN-gamma maturation of dendritic cells induces antigen-Specific CD8+ cytotoxic T cells with high cytolytic potential. Cancer Immunol Immunother 2010; 59: 1185-1195.
123. Dubensky Jr., TW, Reed SG. Adjuvants for cancer vaccines. Semin Immunol 2010;22:155-161.
124. Smits EL, Ponsaerts P, Berneman ZN, Van Tendeloo VFI. The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy. Oncologist 2008;13:859-875.
125. Meyer T, Stockfeth E. Clinical investigations of Toll-like receptor agonists. Expert Opin Investig Drugs 2008;17:1051-1065.
126. Schon MP, Schon M. TLR7 and TLR8 as targets in cancer therapy. Oncogene 2008;27:190-199.
127. Geller M, Cooley S, Argenta P, et al. Toll-like receptor-7 agonist administered subcutaneously in a prolonged dosing schedule in heavily pretreated recurrent breast, ovarian, and cervix cancers. Cancer Immunol Immunother 2010;59:1877-1884.
128. Dudek AZ, Yunis C, Harrison LI, et al. First in human phase I trial of 852A, a novel systemic Tolllike receptor 7 agonist, to activate innate immune responses in patients with advanced cancer. Clin Cancer Res 2007;13:7119-7125. (Pubitemid 350276897)
129. Dummer R, Hauschild A, Becker JC, et al. An exploratory study of systemic administration of the Toll-like receptor-7 agonist 852A in patients with refractory metastatic melanoma. Clin Cancer Res 2008;14:856-864. (Pubitemid 351231170)
130. KriegAM. Development of TLR9 agonists for cancer therapy. J Clin Invest 2007;117:1184-1194. (Pubitemid 46718403)
131. Ashino S, Wakita D, Zhang Y, et al. CpG-ODN inhibits airway infammation at efector phase through down-regulation of antigen-Specific T2-cell migration into lung. Int Immunol 2008;20:259-266. (Pubitemid 351234393)
132. De Cesare M, Sfondrini L, Campiglio M, et al. Ascites regression and survival increase in mice bearing advanced-stage human ovarian carcinomas and repeatedly treated intraperitoneally with CpG-ODN. J Immunother 2010;33:8-15.
133. De Cesare M, Calcaterra C, Pratesi G, et al. Eradication of ovarian tumor xenografts by locoregional administration of targeted immunotherapy. Clin Cancer Res 2008;14:5512-5518.
134. Chuang C-M, Monie A, Wu A, et al. Treatment with LL-37 peptide enhances antitumor effects induced by CpG oligodeoxynucleotides against ovarian cancer. Human Gene Ter 2009;20:303-313.
135. Goldstein MJ, Varghese B, Brody JD, et al. A CpG-loaded tumor cell vaccine induces antitumor CD4+ T cells that are efective in adoptive therapy for large and established tumors. Blood 2011;117:118-127.
136. Sfondrini L, Rossini A, Besusso D, et al. Antitumor activity of the TLR-5 ligand fagellin in mouse models of cancer. J Immunol 2006;176:6624-6630. (Pubitemid 43787845)
137. Whitmore MM, DeVeer MJ, Edling A, et al. Synergistic activation of innate immunity by double-stranded RNA and CpG DNA promotes enhanced antitumor activity. Cancer Res 2004;64:5850-5860. (Pubitemid 39095586)
138. Miles AP, McClellanHA, RauschKM, et al. Montanide® ISA 720 vaccines: Quality control of emulsions, stability of formulated antigens, and comparative immunogenicity of vaccine formulations. Vaccine 2005;23:2530-2539.
139. Lawrence GW, Saul A, Giddy AJ, et al. Phase I trial in humans of an oil-based adjuvant SEPPIC MONTANIDE ISA 720. Vaccine 1997;15:176-178. (Pubitemid 27091248)
140. Genton B, Al-Yaman F, Anders R, et al. Safety and immunogenicity of a three-component blood-stage malaria vaccine in adults living in an endemic area of Papua New Guinea. Vaccine 2000;18:2504-2511. (Pubitemid 30207035)
141. Scalzo A, Elliott S, Cox J, et al. Induction of protective cytotoxic T cells to murine cytomegalovirus by using a nonapeptide and a human-compatible adjuvant (Montanide ISA 720). J Virol 1995;69:1306-1309.
142. Hersey P, Menzies SW, Coventry B, et al. Phase I/II study of immunotherapy with T-cell peptide epitopes in patients with stage IV melanoma. Cancer Immunol Immunother 2005;54:208-218. (Pubitemid 40174239)
143. Hirunpetcharat C, Wipasa J, Sakkhachornphop S, et al. CpG oligodeoxynucleotide enhances immunity against blood-stage malaria infection in mice parenterally immunized with a yeast-expressed 19 kDa carboxyl-terminal fragment of Plasmodium yoelii merozoite surface protein-1 (MSP119) formulated in oil-based Montanides. Vaccine 2003;21:2923-2932. (Pubitemid 36705534)
144. Perlaza BL, Arevalo-Herrera M, Brahimi K, et al. Immunogenicity of four Plasmodium falciparum preerythrocytic antigens in Aotus lemurinus monkeys. Infect Immun 1998;66:3423-3428. (Pubitemid 28303147)
145. Oliveira GA, Wetzel K, Calvo-Calle JM, et al. Safety and enhanced immunogenicity of a Hepatitis B Core particle Plasmodium falciparum malaria vaccine formulated in adjuvant Montanide ISA 720 in a phase I trial. Infect Immun 2005;73:3587-3597. (Pubitemid 40745903)
146. Chianese-Bullock KA, Pressley J, Garbee C, et al. MAGE-A1-, MAGE-A10-, and gp100-derived pep-tides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and Montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma. J Immunol 2005;174:3080-3086. (Pubitemid 40279730)
147. Toledo H, Baly A, Castro O, et al. A phase I clinical trial of a multi-epitope polypeptide TAB9 combined with Montanide ISA 720 adjuvant in non-HIV-1 infected human volunteers. Vaccine 2001;19:4328-4336. (Pubitemid 32703655)
148. Oka Y, Tsuboi A, Taguchi T, et al. Induction of WT1 (Wilms' tumor gene)-Specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci USA 2004;101:13885-13890. (Pubitemid 39298502)
149. Lawrence G, Cheng Q, Reed C, et al. Efect of vaccination with 3 recombinant asexual-stage malaria antigens on initial growth rates of Plasmodium falciparum in non-immune volunteers. Vaccine 2000;18:1925-1931. (Pubitemid 30122856)
150. Odunsi K, Qian F, Matsuzaki J, et al. Vaccination with an NY-ESO-1 peptide of HLA class I/II speci-fcities induces integrated humoral and T cell responses in ovarian cancer. Proc Natl Acad Sci USA 2007;104:12837-12842. (Pubitemid 47255241)
151. Diefenbach CSM, Gnjatic S, Sabbatini P, et al. Safety and immunogenicity study of NY-ESO-1b pep-tide and Montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk frst remission. Clin Cancer Res 2008;14:2740-2748.
152. Valmori D, Souleimanian NE, Tosello V, et al. Vaccination with NY-ESO-1 protein and CpG in Mon-tanide inducesintegrated antibody/T1 responses and CD8Tcells throughcross-priming.Proc Natl Acad Sci USA 2007;104:8947-8952. (Pubitemid 47175417)
153. Lefers N, Lambeck AJA, Gooden MJM, et al. Immunization with a P53 synthetic long peptide vaccine induces P53-Specific immune responses in ovarian cancer patients, a phase II trial. IntJCancer 2009;125:2104-2113.
154. Eisenbarth SC, Colegio OR, O'Connor W, et al. Crucial role for the Nalp3 infammasome in the im-munostimulatory properties of aluminium adjuvants. Nature 2008;453:1122-1126. (Pubitemid 351871731)
155. Hem SL, HogenEsch H. Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation. Expert Rev Vaccines 2007;6:685-698. (Pubitemid 47607846)
156. Morefeld GL, Sokolovska A, Jiang D, et al. Role of aluminum-containing adjuvants in antigen in-ternalization by dendritic cells in vitro. Vaccine 2005;23:1588-1595. (Pubitemid 40203396)
157. Goto N, Akama K. Histopathological studies of reactions in mice injected with aluminum-adsorbed tetanus toxoid. Microbiol Immunol 1982;26:1121-1132. (Pubitemid 13146183)
158. Goto N, Kato H, Maeyama J, et al. Local tissue irritating effects and adjuvant activities of calcium phosphate and aluminium hydroxide with diferent physical properties. Vaccine 1997;15:1364-1371. (Pubitemid 27397815)
159. Kool M, Soullié T, Van Nimwegen M, et al. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating infammatory dendritic cells. J Exp Med 2008;205:869-882. (Pubitemid 351549884)
160. Wagner U, Köhler S, Reinartz S, et al. Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: Immune responses and survival in palliative treatment. Clin Cancer Res 2001;7:1154-1162. (Pubitemid 32708665)
161. Podda A, Del Giudice G. MF59-adjuvanted vaccines: Increased immunogenicity with an optimal safety profle. Expert Rev Vaccines 2003;2:197-204. (Pubitemid 36559925)
162. Kensil C, Patel U, Lennick M, Marciani D. Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex. J Immunol 1991;146:431-437.
163. Kensil C, Kammer R. QS-21: A water-soluble triterpene glycoside adjuvant. Expert Opin Investig Drugs 1998;7:1475-1482. (Pubitemid 28408808)
164. Evans TG, McElrath MJ, Matthews T, et al. QS-21 promotes an adjuvant efect allowing for reduced antigen dose during HIV-1 envelope subunit immmunization in humans. Vaccine 2001;19:2080-2091. (Pubitemid 32178358)
165. Kashala O, Amador R, Valero MV, et al. Safety, tolerability and immunogenicity of new formulations of the Plasmodium falciparum malaria peptide vaccine SPf66 combined with the immunological adjuvant QS-21. Vaccine 2002;20:2263-2277. (Pubitemid 34497037)
166. Gahery-Segard H, Pialoux G, Figueiredo S, et al. Long-term Specific immune responses induced in humans by a human immunodefciency virus type 1 lipopeptide vaccine: Characterization of CD8+-T-Cell epitopes recognized. J Virol 2003 2003;77:11220-11231. (Pubitemid 37204312)
167. Fogg CN, Americo JL, Lustig S, et al. Adjuvant-enhanced antibody responses to recombinant proteins correlates with protection of mice and monkeys to orthopoxvirus challenges. Vaccine 2007;25:2787-2799. (Pubitemid 46412575)
168. Sabbatini PJ, Ragupathi G, Hood C, et al. Pilot study of a heptavalent vaccine-keyhole limpet hemo-cyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer. Clin Cancer Res 2007;13:4170-4177. (Pubitemid 47105980)
169. Gilewski T, Adluri S, Ragupathi G, et al. Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21. Clin Cancer Res 2000;6:1693-1701. (Pubitemid 30305061)
170. Ragupathi G, Livingston PO, Hood C, et al. Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21. Clin Cancer Res 2003;9:5214-5220. (Pubitemid 37413571)
171. Sabbatini P, Spriggs D, Aghajanian C, et al. Consolidation strategies in ovarian cancer: Observations for future clinical trials. Gynecol Oncol 2010;116:66-71.
172. Sandmaier B, Oparin D, Holmberg L, et al. Evidence of a cellular immune response against sialyl-Tn in breast and ovarian cancer patients after high-dose chemotherapy, stem cell rescue, and immunization with Teratope STn-KLH cancer vaccine. J Immunother 1999;22:54-66. (Pubitemid 29042291)
173. Miles D, Papazisis K. Rationale for the clinical development of STn-KLH (Teratope®) and anti-MUC-1 vaccines in breast cancer. Clin Breast Cancer 2003;3:S134-S138.
174. Dranof G. GM-CSF-based cancer vaccines. Immunol Rev 2002;188:147-154.
175. Rosenblatt J, Vasir B, Uhl L, et al. Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma. Blood 2011 Jan 13;117:393-402.
176. Weide B, Carralot J-P, Reese A, et al. Results of the frst phase I/II clinical vaccination trial with direct injection of mRNA. J Immunother 2008;31:180-188.
177. Dai S, Wei D, Wu Z, et al. Phase I clinical trial of autologous ascites-derived exosomes combined with GM-CSF for colorectal cancer. Mol Ter 2008;16:782-790. (Pubitemid 351426181)
178. Dranof G. Tragets of protective tumor immunity. Cancer Vaccines, Annals NY Acad Sci 2009;1174:74-80.
179. Borrello IM, Levitsky HI, Stock W, et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML). Blood 2009;114:1736-1745.
180. Nemunaitis J, Jahan T, Ross H, et al. Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX vaccine in advanced-stage non-small-cell lung cancer. Cancer Gene Ter 2006;13:555-562.
181. Tani K, Azuma M, Nakazaki Y, et al. Phase I study of autologous tumor vaccines transduced with the GM-CSF gene in four patients with stage IV renal cell cancer in Japan: Clinical and immunological fndings. Mol Ter 2004;10:799-816. (Pubitemid 39272869)
182. Nemunaitis J. Granulocyte-macrophage colony-stimulating factor gene-transfected autologous tumor cell vaccine: Focus on non-small-cell lung cancer. Clin Lung Cancer 2003;5:148-157. (Pubitemid 38028804)
183. Robinson HL, Montefori DC, Villinger F, et al. Studies on GM-CSF DNA as an adjuvant for neutralizing Ab elicited by a DNA/MVA immunodefciency virus vaccine. Virology 2006;352:285-294. (Pubitemid 44215994)
184. Dolcetti L, Peranzoni E, Ugel S, et al. Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. Eur J Immunol 2010;40:22-35.
185. Kurbacher C, Kurbacher J, Cramer E, et al. Continuous low-dose GM-CSF as salvage therapy in refractory recurrent breast or female genital tract carcinoma. Oncology (Williston Park) 2005;19(4 Suppl):23-26.
186. Roche MR, Rudd PJ, Krasner CN, et al. Phase II trial of GM-CSF in women with asymptomatic recurrent Müllerian tumors. Gynecol Oncol 2010;116:168-172.
187. de Vries EGE, Biesma B, Willemse PHB, et al. A double-blind placebo-controlled study with granulocyte-macrophage colony-stimulating factor during chemotherapy for ovarian carcinoma. Cancer Res 1991;51:116-122.
188. Schmeler KM, Vadhan-Raj S, Ramirez PT, et al. A phase II study of GM-CSF and rIFN-1b plus carboplatin for the treatment of recurrent, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancer. Gynecol Oncol 2009;113:210-215.
189. Elgueta R, Benson MJ, De Vries VC, et al. Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol Rev 2009;229:152-172.
190. Graf D, Müller S, Korthauer U, et al. A soluble form of TRAP (CD40 ligand) is rapidly released after T cell activation. Eur J Immunol 1995;25:1749-1754.
191. Mazzei GJ, Edgerton MD, Losberger C, et al. Recombinant soluble trimeric CD40 ligand is biologically active. J Biol Chem 1995;270:7025-7028.
192. Cella M, Scheidegger D, Palmer-Lehmann K, et al. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med 1996;184:747-752. (Pubitemid 26324129)
193. Lee BO, Moyron-Quiroz J, Rangel-Moreno J, et al. CD40, but not CD154, expression on B cells is necessary for optimal primary B cell responses. J Immunol 2003;171:5707-5717. (Pubitemid 37467185)
194. Ghamande S, Hylander BL, Ofazoglu E, et al. Recombinant CD40 ligand therapy has signifcant an-titumor effects on CD40-positive ovarian tumor xenografts grown in SCID mice and demonstrates an augmented efect with cisplatin. Cancer Res 2001;61:7556-7562. (Pubitemid 32995048)
195. Vonderheide RH, Flaherty KT, Khalil M, et al. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol 2007;25:876-883. (Pubitemid 350002889)
196. Advani R, Forero-Torres A, Furman RR, et al. Phase I Study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's Lymphoma. J Clin Oncol 2009;27:4371-4377.
197. Johnson PW, Steven NM, Chowdhury F, et al. A Cancer Research UK phase I study evaluating safety, tolerability, and biological effects of chimeric anti-CD40 monoclonal antibody (MAb), Chi Lob 7/4. J Clin Oncol 2010;28 (15s (suppl; abstr 2507)).
198. Scarlett UK, Cubillos-Ruiz JR, Nesbeth YC, et al. In situ stimulation of CD40 and Toll-like receptor 3 transforms ovarian cancer-infltrating dendritic cells from immunosuppressive to immunostim-ulatory cells. Cancer Res 2009;69:7329-7337.
199. Zeigler F, Bennett B, Jordan C, et al. Cellular and molecular characterization of the role of the fk-2/ft-3 receptor tyrosine kinase in hematopoietic stem cells. Blood 1994;84:2422-2430. (Pubitemid 24317371)
200. Rasko J, Metcalf D, Rossner M, et al. The ft3/fk-2 ligand: Receptor distribution and action on murine haemopoietic cell survival and proliferation. Leukemia 1995;12:2058-2066. (Pubitemid 26023790)
201. Rosnet O, Schif C, Pebusque M, et al. Human FLT3/FLK2 gene: cDNA cloning and expression in hematopoietic cells. Blood 1993;82:1110-1119. (Pubitemid 23253983)
202. Shibuya M, Yamaguchi S, Yamane A, et al. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (ft) closely related to the fms family. Oncogene 1990;5:519-524.
203. Hannum C, Culpepper J, Campbell D, et al. Ligand for FLT3/FLK2 receptor tyrosine kinase regulates growth of haematopoietic stem cells and is encoded by variant RNAs. Nature 1994;368:643-648. (Pubitemid 24153389)
204. Lyman SD, James L, Bos TV, et al. Molecular cloning of a ligand for the ft3 fk-2 tyrosine kinase receptor: A proliferative factor for primitive hematopoietic cells. Cell 1993;75:1157-1167. (Pubitemid 24006112)
205. Lyman S, James L, Johnson L, et al. Cloning of the human homologue of the murine ft3 ligand: A growth factor for early hematopoietic progenitor cells. Blood 1994;83:2795-2801.
206. McNeel DG, Knutson KL, Schifman K, et al. Pilot study of an HLA-A2 peptide vaccine using Flt3 ligand as a systemic vaccine adjuvant. J Clin Immunol 2003;23:62-72. (Pubitemid 36207978)
207. Hunte B, Hudak S, Campbell D, et al. fk2/ft3 ligand is a potent cofactor for the growth of primitive B cell progenitors. J Immunol 1996;156:489-496.
208. Ray RJ, Paige CJ, Furlonger C, et al. Flt3 ligand supports the diferentiation of early B cell progenitors in the presence of interleukin-11 and interleukin-7. Eur J Immunol 1996;26:1504-1510. (Pubitemid 26229995)
209. Mackarehtschian K, Hardin JD, Moore KA, et al. Targeted disruption of the fk2/ft3 gene leads to defciencies in primitive hematopoietic progenitors. Immunity 1995;3:147-161.
210. Jacobsen S, Veiby O, Myklebust J, et al. Ability of ft3 ligand to stimulate the in vitro growth of primitive murine hematopoietic progenitors is potently and directly inhibited by transforming growth factor-beta and tumor necrosis factor-alpha. Blood 1996;87:5016-5026.
211. Ohishi K, Katayama N, Itoh R, et al. Accelerated cell-cycling of hematopoietic progenitors by the ft3 ligand that is modulated by transforming growth factor-beta. Blood 1996;87:1718-1727. (Pubitemid 26074097)
212. Freedman RS, Vadhan-Raj S, Butts C, et al. Pilot study of Flt3 ligand comparing intraperitoneal with subcutaneous routes on hematologic and immunologic responses in patients with peritoneal car-cinomatosis and mesotheliomas. Clin Cancer Res 2003;9:5228-5237. (Pubitemid 37413573)
213. Disis ML, Rinn K, Knutson KL, et al. Flt3 ligand as a vaccine adjuvant in association with HER-2/neu peptide-based vaccines in patients with HER-2/neu-overexpressing cancers. Blood 2002;99:2845-2850. (Pubitemid 34525373)
214. Matsumura N, Mandai M, Hamanishi J, et al. Immunostimulatory efect of Fms-like tyrosine ki-nase 3 ligand on peripheral monocyte-derived dendritic cells and natural killer cells: Utilization for ovarian cancer treatment. Oncol Rep 2008;19:505-515. (Pubitemid 351176114)
215. Silver DF, Hempling RE, Piver MS, Repasky EA. Flt-3 ligand inhibits growth of human ovarian tumors engrafted in severe combined immunodefcient mice. Gynecol Oncol 2000;77:377-382. (Pubitemid 30368553)
216. Sudo Y, Shimazaki C, Ashihara E, et al. Synergistic efect of FLT-3 ligand on the granulocyte colony-stimulating factor-induced mobilization of hematopoietic stem cells and progenitor cells into blood in mice. Blood 1997;89:3186-3191.
217. Geiger JD, Hutchinson RJ, Hohenkirk LF, et al. Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand Specific T cells and mediate tumor regression. Cancer Res 2001;61:8513-8519. (Pubitemid 33131133)
218. Stift A, Friedl J, Dubsky P, et al. Dendritic cell-based vaccination in solid cancer. J Clin Oncol 2003;21:135-142.
219. Chang AE, Redman BG, Whitfeld JR, et al. A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer. Clin Cancer Res 2002;8:1021-1032. (Pubitemid 35177351)
220. Janetzki S, Palla D, Rosenhauer V, et al. Immunization of cancer patients with autologous cancer-derived heat shock protein gp96 preparations: a pilot study. Int J Cancer 2000;88:232-238.
221. Berd D. Autologous, hapten-modifed vaccine as a treatment for human cancers. Vaccine 2001;19:2565-2570. (Pubitemid 32234273)
222. Chianese-Bullock KA, Irvin WPJ, Petroni GR, et al. A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer. I Immunothera 2008;31:420-430. (Pubitemid 351595165)
223. Morse MA, Alvarez Secord A, Blackwell KL, et al. MHC class I-presented tumor antigens identifed in ovarian cancer by immunoproteomic analysis are targets for T cell responses against breast and ovarian cancer. Clin Cancer Res 2011 Feb 7. DOI:10.1158/1078-0432. CCR-10-2614.